Literature DB >> 4139404

Results of administering B.C.G. to patients with melanoma.

R M Grant, R Mackie, A J Cochran, E L Murray, D Hoyle, C Ross.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4139404     DOI： 10.1016/s0140-6736(74)90867-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  The role of immunotherapy in the management of patients with malignant melanoma.

Authors:  J E Goodnight; D L Morton
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

2.  Controlled trial of active immunotherapy in management of stage IIB malignant melanoma.

Authors:  M B McIllmurray; M J Embleton; W G Reeves; M J Langman; M Deane
Journal:  Br Med J       Date:  1977-02-26

3.  T- and B-lymphocyte subpopulations in pre-invasive and invasive carcinoma of the cervix.

Authors:  R J Rand; D M Jenkins; R Bulmer
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

4.  BCG and cancer.

Authors: 
Journal:  Can Med Assoc J       Date:  1975-10-18       Impact factor: 8.262

5.  Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma.

Authors:  J W Millar; P Roscoe; S J Pearce; S Ludgate; N W Horne
Journal:  Thorax       Date:  1982-01       Impact factor: 9.139

6.  Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha.

Authors:  J L Haley; D G Young; A Alexandroff; K James; A M Jackson
Journal:  Immunology       Date:  1999-01       Impact factor: 7.397

7.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.